Sequenom Inc., a life sciences company in San Diego, announced that it has entered into a clinical research collaboration with the University of California, San Diego Moores Cancer Center.
Under this collaboration, Moores Cancer Center will use Sequenom's new liquid biopsy test to help choose the right therapies for cancer patients. This technology, which profiles circulating cell-free tumor DNA in the blood, has the potential to overcome the challenges and limitations associated with current methods such as imaging and invasive biopsies.
"The ability to match patients to a growing list of treatments and to monitor their response by a simple blood draw promises to make a significant difference in the way we treat cancer patients at UC San Diego," said Dr. Razelle Kurzrock, chief of the Division of Hematology & Oncology and Murray Professor of Medicine, senior deputy director of Clinical Science and director of the Center for Personalized Cancer Therapy & Clinical Trials Office. "The collaboration with Sequenom will allow us to analyze more cancer-related genes in the blood than previously possible to better understand tumor heterogeneity and the emergence of resistance mutations."
The collaboration with UC San Diego Moores Cancer Center is the first of a series of collaborations with leading cancer centers worldwide that will utilize the assay as part of their clinical research programs. Sequenom, through its wholly owned subsidiary Sequenom Laboratories, intends to carry out further studies in order to bring to market a liquid biopsy assay for use in patient care in 2016.